Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu‐DOTAGA‐PEG 2 ‐RM26

Bogdan Mitran,Sara S. Rinne,Mark Konijnenberg,Theodosia Maina,Berthold A. Nock,Mohamed Altai,Anzhelika Vorobyeva,Mats Larhed,Vladimir Tolmachev,Marion de Jong,Ulrika Rosenström,Anna Orlova

Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu‐DOTAGA‐PEG 2 ‐RM26

2019

Bogdan Mitran
Sara S. Rinne
Mark Konijnenberg
Theodosia Maina
Berthold A. Nock
Mohamed Altai
Anzhelika Vorobyeva
Mats Larhed
Vladimir Tolmachev
Marion de Jong
Ulrika Rosenström
Anna Orlova

Gastrin-releasing peptide receptors (GRPRs) are overexpressed in prostate cancer and are suitable for targeted radionuclidetherapy (TRT). We optimized the bombesin-derived GRPR-antagonist PEG2-RM26 ...

Keywords:

Cancer research
Prostate cancer
Trastuzumab
Antagonist
PEG ratio
Medicine
Receptor
Peptide
radionuclide therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations